

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-11. (Cancelled):

12. (Currently Amended): A compound according to Claim 1, wherein said compound is selected from:

~~*N*-methyl-4-{4-[5-(4-chloro-3-trifluoromethylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,~~

~~*N*-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,~~

~~*N*-methyl-4-{3-[5-(4-chloro-3-trifluoromethylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,~~

~~*N*-methyl-4-{3-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,~~

~~*N*-methyl-4-{4-[5-(3-chloro-4-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide,~~

~~*N*-methyl-4-{4-[5-(2-methoxy-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,~~

~~*N*-methyl-4-{3-[5-(3-chloro-4-methylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,~~

~~*N*-methyl-4-{3-[5-(3-chloro-4-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide,~~

~~*N*-methyl-4-{4-[5-(3-chloro-6-methoxymethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,~~

~~*N*-methyl-4-{4-[5-(3-chloro-6-methoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide,~~

~~*N*-methyl-4-{3-[5-(3-chloro-6-methoxymethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-~~

phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3-chloro-6-methoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-methoxy-5-trifluoromethylmethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-methoxy-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2,5-dimethoxy-4-chlorophenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-bromo-3-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3-trifluoromethoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-tert-butylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(3,4-dichlorophenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(4-chloro-3-methyl-6-methoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2,4-dimethoxy-5-trifluoromethoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-dimethylamino-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,


N-methyl-4-{3-[5-(2-(2-methylaminoethoxy)-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

N-methyl-4-{3-[5-(2-(2-dimethylaminoethoxy)-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,

*N*-methyl-4-{3-[5-(2-[(2-dimethylaminoethyl)methylamino]-5-methyl-phenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide,  
and pharmaceutically acceptable ~~usable derivatives, solvates,~~ salts and stereoisomers thereof, including mixtures thereof in all ratios.

13. (Currently Amended): A process for the preparation of a compound according to 12 claim 1, said process comprising:

a) ~~for a compound in which Y denotes O,~~  
reacting a compound of formula II



wherein L is Cl, Br, I or a free or reactively functionally modified OH group, X is O, and Ar is pyridinyl,

with a compound of formula III



wherein Z is 4-chloro-3-trifluoromethylphenyl, 3-chloro-4-methylphenyl, 2-methoxy-5-trifluoromethylphenyl, 3-chloro-6-methoxyphenyl, 2,5-dimethoxy-4-chlorophenyl, 4-bromo-3-trifluoromethylphenyl, 3-trifluoromethoxyphenyl, 4-tert-butylphenyl, 3,4-dichlorophenyl, 4-chloro-3-methyl-6-methoxyphenyl, 2,4-dimethoxy-5-trifluoromethoxyphenyl, 2-dimethylamino-5-trifluoromethylphenyl, 2-dimethylamino-5-trifluoromethylphenyl, 2-(2-methylaminoethoxy)-5-methylphenyl, 2-(2-dimethylaminoethoxy)-5-methyl, or 2-[(2-dimethylaminoethyl)methylamino]-5-methylphenyl,  
and/or

and, if the resultant compound is a base or acid, optionally converting said [[a]] base or acid of formula-I into a pharmaceutically acceptable salt thereof one of its salts.

14. (Currently Amended): A pharmaceutical composition comprising at least one compound according to Claim 12 + and at least one excipient and/or adjuvant.

15. (Cancelled):

16. (Cancelled):

17. (Cancelled):

18. (Cancelled):

19. (Cancelled):

20. (Cancelled):

21. (Cancelled):

22. (Withdrawn; Currently Amended): A method for the treatment of a non-cancerous disease according to Claim 21, wherein said non-cancerous disease is psoriasis, arthritis, inflammation, endometriosis, scarring, Helicobacter pylori infection, influenza A, benign prostate hyperplasia, an immunological disease, an autoimmune disease, or an immunodeficiency disease, said method comprising administering to a patient a compound according to claim 12.


23. (Withdrawn; Currently Amended): A method for the treatment of a disease which is caused, mediated and/or propagated by Raf kinases according to claim 17, wherein said disease is melanoma, brain cancer, lung cancer, squamous epithelium cancer, bladder cancer, stomach cancer, pancreatic cancer, liver cancer, kidney cancer, colorectal cancer,

breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian cancer, cervical cancer, prostate cancer, thyroid cancer, lymphoma, chronic leukaemia, or acute leukaemia, said method comprising administering to a patient a compound according to claim 12.

24. (Withdrawn; Currently Amended): A method for the treatment of a disease selected from according to claim 15, wherein said disease is arthritis, restenosis, fibrotic disorder, disorders mesangial cell proliferation, diabetic nephropathy, malignant nephrosclerosis, a thrombotic microangiopathy syndrome, an organ transplant rejection, a glomerulopathy, a metabolic disorder, inflammation, a solid tumour, rheumatic arthritis, diabetic neuropathy, or a neurodegenerative disease, said method comprising administering to a patient a compound according to claim 12.

25. (Withdrawn; Currently Amended): A method for the treatment of a disease selected from according to claim 15, wherein said disease is rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, irritable bowel, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, kidney disease, or a and angiogenesis disorder, said method comprising administering to a patient a compound according to claim 12.

26. (Withdrawn; Currently Amended): A compound of formula I-1



wherein

Ar is ~~pyridinyl phenyl, naphthyl, biphenyl or Het,~~ each of which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted by R<sup>1</sup>,

X is ~~-O-, -S-, (CH<sub>2</sub>)<sub>n</sub>-, C(=O)-, CH(OH)-, (CH<sub>2</sub>)<sub>n</sub>O-, O(CH<sub>2</sub>)<sub>n</sub>-, (CH<sub>2</sub>)<sub>n</sub>S-,  
-S(CH<sub>2</sub>)<sub>n</sub>-, (CH<sub>2</sub>)<sub>n</sub>NH-, NH(CH<sub>2</sub>)<sub>n</sub>-, (CH<sub>2</sub>)<sub>n</sub>NA-, NA(CH<sub>2</sub>)<sub>n</sub>-, CHHal-, or  
-C(Hal)<sub>2</sub>-~~

R is H or A,

~~Het is a mono or bicyclic aromatic heterocycle having 1 to 4 N, O and/or S atoms;~~

R<sup>1</sup> is A, Ar', OR<sup>3</sup>, SR<sup>3</sup>, OAr', SAR', N(R<sup>3</sup>)<sub>2</sub>, NHA', Hal, NO<sub>2</sub>, CN, (CH<sub>2</sub>)<sub>m</sub>COOR<sup>3</sup>,  
(CH<sub>2</sub>)<sub>m</sub>CON(R<sup>3</sup>)<sub>2</sub>, COR<sup>3</sup>, S(O)<sub>m</sub>A, S(O)<sub>m</sub>Ar', NHCOA, NHCOAr', NHSO<sub>2</sub>A,  
NHSO<sub>2</sub>Ar', or SO<sub>2</sub>N(R<sup>3</sup>)<sub>2</sub>,

R<sup>3</sup> is H, A or -(CH<sub>2</sub>)<sub>n</sub>Ar'-,

Ar' is phenyl which is unsubstituted or mono-, di-, tri-, tetra- or pentasubstituted  
by A, Ph, OH, OA, SH, SA, OPh, SPh, NH<sub>2</sub>, NHA, NA<sub>2</sub>, NHPh, Hal, NO<sub>2</sub>,  
CN, (CH<sub>2</sub>)<sub>m</sub>COOH, (CH<sub>2</sub>)<sub>m</sub>COOA, (CH<sub>2</sub>)<sub>m</sub>CONH<sub>2</sub>, (CH<sub>2</sub>)<sub>m</sub>CONHA, CHO,  
COA, S(O)<sub>m</sub>A, S(O)<sub>m</sub>Ph, NHCOA, NHCOPh, NHSO<sub>2</sub>A, NHSO<sub>2</sub>Ph, or  
SO<sub>2</sub>NH<sub>2</sub>,

Ph is phenyl which is unsubstituted or mono-, di- or trisubstituted by A, Hal, CN,  
COOR, COOH, NH<sub>2</sub>, NO<sub>2</sub>, OH or OA,

A is alkyl having 1 to 10 C atoms wherein 1-7 H atoms are each optionally  
replaced by F and/or chlorine,

Hal is F, Cl, Br or I, and

~~n is 0, 1, 2 or 3, and~~

m is 0, 1 or 2, or

a solvate, salt, or stereoisomer thereof, including mixtures thereof in all ratios.

27. (Withdrawn; Currently Amended): A compound according to Claim 26,

wherein R<sup>1</sup> is (CH<sub>2</sub>)<sub>m</sub>CONH<sub>2</sub>, (CH<sub>2</sub>)<sub>m</sub>CONHA, or (CH<sub>2</sub>)<sub>m</sub>CONA<sub>2</sub>.

~~X is O,~~

~~Ar is Het which is unsubstituted or mono-, di- or trisubstituted by R<sup>1</sup>;~~

~~R is H or A,~~

~~R<sup>1</sup> is (CH<sub>2</sub>)<sub>m</sub>CONH<sub>2</sub>, (CH<sub>2</sub>)<sub>m</sub>CONHA, or (CH<sub>2</sub>)<sub>m</sub>CONA<sub>2</sub>, and~~

~~Het is a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms.~~

28. (Cancelled):

29. (Cancelled):

30. (Cancelled):

31. (Cancelled):

32. (Cancelled):

33. (Cancelled):

34. (Cancelled):

35. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

36. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

37. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{4-[5-(3-chloro-4-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

38. (New): A compound according to Claim 12, wherein said compound is *N*-

methyl-4-{4-[5-(2-methoxy-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

39. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(3-chloro-4-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

40. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{4-[5-(3-chloro-6-methoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

41. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(3-chloro-6-methoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

42. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(2-methoxy-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

43. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(2,5-dimethoxy-4-chlorophenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

44. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(4-bromo-3-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

45. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(3-trifluoromethoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-



carboxamide, or a pharmaceutically acceptable salt thereof.

46. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(4-*tert*-butylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

47. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(3,4-dichlorophenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

48. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(4-chloro-3-methyl-6-methoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}-pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

49. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(2,4-dimethoxy-5-trifluoromethoxyphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

50. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(2-dimethylamino-5-trifluoromethylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

51. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(2-(2-methylaminoethoxy)-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

52. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(2-(2-dimethylaminoethoxy)-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.

53. (New): A compound according to Claim 12, wherein said compound is *N*-methyl-4-{3-[5-(2-[(2-dimethylaminoethyl)methylamino]-5-methylphenylcarbamoyl)-1*H*-pyrrol-3-yl]phenoxy}pyridine-2-carboxamide, or a pharmaceutically acceptable salt thereof.